Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
Combination of Autophagy Selective Therapeutics (COAST) in Advanced Solid Tumors or Relapsed Prostate Cancer, a Phase I/II Trial
NCT Number:
NCT05036226
Phase:
I/II
Protocol Type:
Treatment
Age Group:
Adult
Disease Sites:
Anus, Bones and Joints, Brain and Nervous System, Breast, Cervix Uteri, Colon, Corpus Uteri, Esophagus, Eye and Orbit, Larynx, Other Female Genital, Prostate
Study Objectives:
Autophagy is a cancer cell survival mechanism that is involved in cancer growth, treatment resistance, and metastasis. Hydroxychloroquine and nelfinavir mesylate are agents that inhibit the process of autophagy. Metformin, dasatinib, and sirolimus stress autophagy.
For more information about the trial above please contact the study team:
Trial opened at the following institutions: Medical University of South Carolina
Study Documents
(MUSC NetID required for document access)